Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

Kwonjune J. Seung; Palwasha Khan; Molly F. Franke; Saman Ahmed; Stalbek Aiylchiev; Manzur Alam; Fauziah Asnely Putri; Mathieu Bastard; Wisny Docteur; Gary Gottlieb; Catherine Hewison; Shirajul Islam; Naira Khachatryan; Tinatin Kotrikadze; Uzma Khan; Andargachew Kumsa; Leonid Lecca; Yoseph Tassew; Nara Melikyan; Ye Yint Naing; Lawrence Oyewusi; Michael Rich; Stephen Wanjala; Askar Yedilbayev; Helena Huerga; Carole D. Mitnick

doi:10.1093/cid/ciz1084

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Seung et al. (2019) studied this question.

synapsesocial.com/papers/6a951730a35b9ad7aee62821 https://doi.org/10.1093/cid/ciz1084

View at Publisher

Ask AI

Bookmark

Share

Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

Ask about this paper

Abstract

Discussion

Cite This Study

Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading